Validating Immunotherapy in Alzheimer’s Disease: The EB101 Vaccine

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|22|7|849-858

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.22, Iss.7, 2016-02, pp. : 849-858

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immunotherapy in a Rabbit Model of Alzheimer’s Disease

By S. Woodruff-Pak Diana   Shriver Christina   Agelan Alexis   M. Manns Joanne   Coico Richard  

Drug Delivery Letters, Vol. 2, Iss. 1, 2012-03 ,pp. : 14-21

Bentham Science Publishers

Access to resources Recommend Favorite

A phase II trial of the new immunotherapy agent, Alzheimer's disease vaccine [AN-1792],

By  

Inpharma, Vol. 1, Iss. 1326, 2002-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Alzheimer’s Disease

By  

Cells Tissues Organs, Vol. 162, Iss. 1, 1998-10 ,pp. : 46-55

Karger

Access to resources Recommend Favorite

Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy

By  

Current Neuropharmacology, Vol. 11, Iss. 5, 2013-09 ,pp. : 491-498

Bentham Science Publishers

Access to resources Recommend Favorite

Subcellular Injuries in Alzheimer’s Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 4, 2014-06 ,pp. : 593-605

Bentham Science Publishers

Access to resources Recommend Favorite